Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., announced that for the first time in the company’s history, revenue earned on innovation programs surpassed that of generic projects.

Over the past five years, innovation revenue has grown from 35% of total to more than 50%, representing a CAGR of 20%. The 50% figure represents work performed for pharma innovator customers across discovery, development and on-patent commercial manufacturing. It includes projects spanning preclinical development through Phases I, II, and III. This growth far outpaces the annual growth rate of Piramal Pharma’s overall CDMO business.

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “Achieving this threshold is a significant milestone in the history of Piramal Pharma Solutions. For many years, our organizational strategies and tactics have focused on building the expertise and capabilities required to fully support innovator work. This breakthrough validates our efforts and secures our position as an innovator CDMO that support customers in their quest to bring new, patient-centric medicines to regulated markets around the world.”

The growth in innovation revenue is consistent with Piramal Pharma’s success in delivering high value services, including high potency active pharmaceutical ingredients (HPAPIs), antibody-drug conjugations, peptide APIs, sterile fill/finish, and integrated programs, which encompass work conducted at more than one of the company’s fifteen global sites. Integrated programs offer compelling value propositions to customers such as reduced time-to-market, simplified operational complexity, and reduced supply chain costs. Piramal Pharma Solutions has successfully delivered more than 125 integrated programs to date, with many others currently underway.